Asthma & Related Lung Disease

A florist with severe asthma tests positive for both allergic and eosinophilic pathways — a case about which biomarker actually drives a first biologic choice.

A relapsing ABPA case where adding itraconazole surfaces a real CYP3A4 interaction with the patient's own inhaled corticosteroid.

A patient falls just short of full ABPA criteria — a case about whether a diagnostic threshold should determine which therapy comes first.

A baker with confirmed flour-induced occupational asthma weighs guideline-preferred removal against the real cost of leaving his only trade.

A bird fancier's lung case where antigen avoidance came too late — a case about treating fibrotic hypersensitivity pneumonitis once decline continues past removal.

A new EGPA diagnosis with asymptomatic cardiac involvement tests whether the biologic era's real advances apply to an organ-threatening presentation.

A patient asking about allergy shots for rhinitis turns out to be a real candidate for asthma-modifying immunotherapy — if his own numbers clear the right bar.

A patient's IgE and weight fall outside every cell of the omalizumab dosing table — a case about choosing a biologic when the best-matched drug has no defined dose.

Five exacerbation-free years on omalizumab raise a real question — a case about how to safely test whether a long-term biologic is still needed.

A patient's asthma biomarkers are all negative or borderline — a case about choosing a biologic when no single marker points clearly to a phenotype.

A patient still exacerbating four months into omalizumab raises a real question — how long counts as an adequate trial before switching biologics.

A pregnant woman on long-term omalizumab asks whether to stop — a case about weighing registry safety data against the real risks of uncontrolled asthma in pregnancy.